Suppr超能文献

欧洲药品评价局与欧洲新的制药程序。欧洲药品评价局。

EMEA and the new pharmaceutical procedures for Europe. European Medicines Evaluation Agency.

作者信息

Jefferys D B, Jones K H

机构信息

Medicines Control Agency, London, UK.

出版信息

Eur J Clin Pharmacol. 1995;47(6):471-6. doi: 10.1007/BF00193696.

Abstract

The regulation of medicines throughout Europe has undergone significant change since the first pharmaceutical Directive in 1965. 1995 will bring the next major stage in this evolution with the introduction of the so-called "Future System proposals". These will see the creation of the EMEA (the European Medicines Evaluation Agency), the introduction of a Centralized Procedure, applicable to a small number of innovative drugs, and a Decentralized Procedure, based on mutual recognition of licences granted by existing control authorities in other EC countries. The regulation of medicines in the United Kingdom has also changed considerably since the establishment of the Medicines Control Agency in 1989. This article looks at the new licensing arrangements for Europe and the development of medicines control in the UK over the last few years.

摘要

自1965年首个药品指令发布以来,欧洲药品监管发生了重大变化。1995年将随着所谓的“未来体系提案”的引入,迎来这一演变的下一个主要阶段。这些提案将促成欧洲药品评估局(EMEA)的设立,引入适用于少数创新药物的集中程序,以及基于相互认可其他欧盟国家现有监管当局颁发的许可证的分散程序。自1989年药品控制局成立以来,英国的药品监管也发生了很大变化。本文探讨了欧洲新的许可安排以及英国过去几年药品监管的发展情况。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验